Cochlear-backed Epiminder has its sights set on an Australian initial public offering after securing Food and Drug Administration approval for its flagship Minder device.
The medtech, which has spent eight years developing its sub-scalp device to detect seizures for epilepsy patients, will announce on Tuesday that it’s received clearance to market its device in the US.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.